Condition: Diabetes Mellitus, Type 2 · Sponsor: Novo Nordisk A/S
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Siloam Hospitals Lippo Village | Tangerang, Banten, Indonesia | Not Yet Recruiting |
| Siloam Hospitals Surabaya | Surabaya, East Java, Indonesia | Enrolling By Invitation |
| University Malaya Medical Centre | Lembah Pantai, Kuala Lumpur, Malaysia | Enrolling By Invitation |
| National Heart Institute | Kuala Lumpur, Malaysia | Not Yet Recruiting |
| The Medical City Ortigas | Pasig, National Capital Region, Philippines | Not Yet Recruiting |
| Novo Nordisk Investigational Site | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07532863